Get the Stockscreener App
25.22
0.72%
0.18
Pre-market:
25.31
0.09
+0.36%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $25.22, with a volume of 61.90M.
It is up +0.72% in the last 24 hours and up +1.86% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$25.04
Open:
$25.11
24h Volume:
61.90M
Relative Volume:
0.93
Market Cap:
$143.39B
Revenue:
$62.79B
Net Income/Loss:
$9.84B
P/E Ratio:
14.70
EPS:
1.7156
Net Cash Flow:
$10.38B
1W Performance:
+0.56%
1M Performance:
+1.86%
6M Performance:
+8.15%
1Y Performance:
-1.68%
1-Day Range:
$25.05
$25.47
1-Week Range:
$24.28
$25.52
52-Week Range:
$20.91
$27.69
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.22 | 142.37B | 62.79B | 9.84B | 10.38B | 1.7156 |
|
LLY
Lilly Eli Co
|
1,070.16 | 948.45B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
206.05 | 491.26B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
229.51 | 417.60B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
126.54 | 244.28B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.40 | 242.64B | 63.90B | 19.05B | 13.05B | 7.5596 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Is This the Best Value Stock to Buy While Markets Are Volatile? - The Motley Fool
Should FDA Approval of PADCEV-Keytruda Combo Shape the Outlook for Pfizer (PFE) Investors? - Yahoo Finance
Should FDA Approval of PADCEV Plus Keytruda Shift Pfizer's (PFE) Oncology Innovation Outlook? - simplywall.st
Which Is A Better Pick: Johnson & Johnson or Pfizer Stock? - Trefis
Guggenheim Raises Price Target for Pfizer (PFE) to $35 | PFE Sto - GuruFocus
Guggenheim Adjusts Price Target on Pfizer to $35 From $33, Maintains Buy Rating - MarketScreener
14 Stocks Jim Cramer Recently Shed Light On - Insider Monkey
MCC STEM students and employees visit Pfizer - Lowell Sun
A Look at Pfizer's Valuation Following FDA Approval of PADCEV Combination Therapy for Bladder Cancer - simplywall.st
2 Healthcare Stocks for Beginner Investors With a 20-Year Time Horizon - Finviz
Pfizer Secures a Major Regulatory Win—How Will Its U.S. Drug Pricing Deal Shape 2026? - Smartkarma
Does Pfizer’s AI-Powered R&D Signal a New Opportunity for 2025? - Yahoo Finance
Pfizer, UnitedHealth, Viatris, Addus HomeCare, and Quest Stocks Trade Up, What You Need To Know - The Globe and Mail
Pfizer Inc. (PFE) Completes Significant Public Offering of Notes - GuruFocus
Pfizer completes $6 billion public notes offering across multiple maturities - Investing.com
Pfizer completes $6 billion public notes offering across multiple maturities By Investing.com - Investing.com India
Pfizer Sells $6 Billion of Notes - MarketScreener
Pfizer Completes $5 Billion Public Offering - TipRanks
Pfizer Inc. stock outperforms competitors on strong trading day - MarketWatch
Why Are Shares of Pfizer Up Today? - Benzinga
Pfizer, Astellas Say FDA Approves Padcev-Keytruda Combo in Bladder Cancer - MarketScreener
Pfizer (PFE) Gains FDA Approval for New Bladder Cancer Treatment - GuruFocus
mRNA flu shot shows better results than traditional vaccine in trial - upi.com
Pfizer Stock Today (PFE): mRNA Flu Breakthrough, $6B Metsera Bonds and a 7% Dividend – Nov. 21, 2025 - ts2.tech
Pfizer's New mRNA Flu Vaccine Outperforms Traditional Shot Against Predominant StrainsPfizer (NYSE:PFE) - Benzinga
New Trial Shows Pfizer’s mRNA Flu Shot Beats Traditional Flu Vaccine - Citizen Tribune
Is Trending Stock Pfizer Inc. (PFE) a Buy Now? - Yahoo Finance
Medical Morphine Market Deep Research Report with Forecast - openPR.com
Necrotizing Fasciitis Market to Witness Remarkable Growth With - openPR.com
Amazon and Pfizer plunder $22bn on final approach to Thanksgiving - GlobalCapital
Pfizer (PFE) Agrees to $41.5 Million Settlement Over Drug Allega - GuruFocus
Is Pfizer's 6.9%-Yielding Dividend Still Safe? - The Globe and Mail
Pfizer scores a win for mRNA vaccines with influenza data - The Pharma Letter
Pfizer Is Giving Up on BioNTech. Should You Ditch BNTX Stock Now Too? - Barchart.com
HK-listed Hbm climbs to six-week high on licence deal with Pfizer - TradingView
Pfizer aims to seek oral obesity treatments worldwide following Metsera purchase – CEO - MSN
Pfizer: Is This Pharma Giant Finally A Bargain (NYSE:PFE) - Seeking Alpha
Pfizer, Tris Pharma Settle Texas ADHD Drug Case for $41.5 Million - MarketScreener
Pursuing the Next Breakthrough in Cancer Cachexia - Pfizer
Arbutus Reports Major Advances in HBV Candidate as Litigation Against Moderna, Pfizer Builds Toward Trial - MyChesCo
Pfizer, Tris Pharma Reach $41.5M Settlement in Texas ADHD Drug Fraud Suit - USA Herald
Pfizer To Pay $41.5M To Settle Adulterated ADHD Drug Claims - Law360
Pfizer in $41.5 million settlement with Texas over ADHD drug for children - WKZO
Pfizer, Tris Pharma Reach $41.5 Million Settlement With Texas Over Alleged Adulterated ADHD Medicine - MarketScreener
Pfizer (PFE) and Tris Pharma Settle ADHD Drug Lawsuit for $41.5M - GuruFocus
Pfizer, Tris Pharma To Pay Texas $41.5 Million in ADHD Drug Suit - news.bloomberglaw.com
Jefferies 25: Pfizer Still Hungry For Anti-Obesity Deals After Metsera - Citeline News & Insights
Pfizer resolves Texas lawsuit over adulterated ADHD drug in $41.5M settlement - Seeking Alpha
Vitiligo Market Analysis and Forecasts 2025-2035 Featuring Abbvie, Incyte, Amgen, Pfizer, Clinuvel Pharmaceuticals, TWi Biotech, and Arcutis BiotherapeuticsResearchAndMarkets.com - The AI Journal
Pfizer Stock News Today (PFE): Texas ADHD Settlement, New Antibody Partnership and Obesity Push – November 19, 2025 - ts2.tech
Pfizer CEO on plans to bring down drug prices - Yahoo Finance
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.58%
2.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):